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intensity of chemotherapy, which is crucial for tumor control and patient survival. In clinical practice, neutropenia is the main limiting factor for the applicability of chemotherapy. 1 Thereby, both the duration of Grade 4 neutropenia (defined as absolute neutrophil count [ANC] of < 0.5 × 10 9 /L) and the depth of the nadir after chemotherapy are correlated with the development of infectious complications. 2 Thus, an important goal in oncological practice is the prevention of neutropenia when administering chemotherapy.
Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF), which stimulates the production of neutrophil precursors, enhances the function of mature neutrophils, and ameliorates neutropenia and its complications. 3 Pegfilgrastim is a pegylated form of filgrastim, developed to increase the half-life.
Pegfilgrastim retains the same biological activity as filgrastim and binds the same G-CSF receptor. A once-per-chemotherapy-cycle administration of pegfilgrastim was shown to be sufficient to reduce the duration of severe neutropenia as effectively as daily treatment with filgrastim.
4
The efficacy and safety of pegfilgrastim for the prevention of 
| MATERIAL S AND ME THODS
This randomized, double-blind, single-dose, two-way crossover study in healthy subjects was conducted at two study sites in Manufacturing Practice. The protocol and informed consent form were reviewed and approved by relevant ethics committees prior to implementation. Written informed consent was obtained from all subjects prior to screening.
| Study population
Healthy male subjects (as determined by medical history, physical examination including vital signs, electrocardiogram [ECG] , and clinical laboratory testing), aged 18-55 years, with a body mass index (BMI) between 20.0 and 30.0 kg/m 2 (inclusive), and a weight between 60 and 100 kg (inclusive) were eligible to be included in the study. All subjects were to comply with the contraception requirements as specified in the protocol. Subjects were excluded if they had been previously treated with pegfilgrastim, or if they had known anti-drug antibodies (ADAs) to filgrastim, pegfilgrastim, or polyethylene glycol (PEG).
| Study design
The sample size was determined by the anticipated variability of the PK endpoints AUC 0-last and C max , for which the intra-individual coefficient of variation (CV) was expected to be high, but not ex- The study design is shown in Figure 1 .
Subjects were screened 2 to 28 days prior to administration of study drug. Eligible subjects were admitted to the study site and re- 
| Endpoints and statistical analysis
The primary PK endpoints were AUC 0-last and C max . The primary PK analysis was performed on the model-based PK set (defined as all subjects with reliable PK data for both study periods ie without any important protocol deviation which would render the data between treatments incomparable). For AUC 0-last and C max the (1−2α)% CI for the ratio of the test and reference products was to be contained within the equivalence margin of 80.0%-125.0%. The primary PK parameters were evaluated using an α1-level of 0.0284 (corresponding to a 94.32% CI for the test/reference ratio). For Stage 1, the 94.32% confidence limits were calculated based on the antilogs of the least square means and mean square error from a general linear model (GLM) analysis of variance with sequence, subjects within sequence, period and treatment as fixed effects on log-transformed data. In order to achieve a better approximation to a normal distribution, PK parameters related to concentrations (such as AUC 0-last and C max ) were logarithmically transformed before analysis. Secondary PK endpoints included time to C max (t max ), terminal elimination rate constant (λ z ), half-life (t ½ ); these were evaluated descriptively. The primary PD endpoint was AUEC 0-last for ANC. The primary PD analysis was performed on the modelbased PD set (defined as all subjects with reliable PD data for both study periods ie without any important protocol deviation which would render the data between treatments incomparable).
Pelmeg and Neulasta were assumed to be comparable if the 95%
CI of the test/reference ratio is within the equivalence margin of 80.0%-125.0%. The 95% confidence limits were calculated based on the antilogs of the least square means and mean square error from a GLM analysis of variance with sequence, subjects within sequence, period and treatment as fixed effects on log-transformed AUEC 0-last of ANC data. To achieve a better approximation to a normal distribution, PD parameters related to concentrations (such as AUEC 0-last ) were logarithmically transformed before analysis. The secondary PD endpoints maximum effect (E max ) and t max,E of ANC, and CD34 + counts were evaluated descriptively. Safety variables included adverse events (AEs), local tolerability, physical examinations, vital signs, 12-lead ECG, and laboratory safety assessments. Immunogenicity was investigated by assessment of
ADAs. Safety results were summarized descriptively.
| Bioanalysis

| Analysis of pegfilgrastim concentrations
Blood samples for PK analysis were collected during the in-patient 
| Analysis of ANC and CD34
Blood samples for determination of ANC were collected during the inpatient phase, predose, and up to 96 hours postdose, and during the ambulatory visits in each period. Determination of ANC from whole blood was performed by fluorescent flow cytometry, using the auto- is an FDA cleared in vitro diagnostic test which meets the ISHAGE Guidelines. 11 The sensitivity of the assay was determined as 2.7
CD34+ cells/µL. The assay was found to be precise, with ≤ 30% CV.
| Analysis of ADAs
Blood samples for ADA analysis were obtained on Day 1 predose, Days 8, 15, 22, 29 of each period, and Day 43 of the last period.
Anti-pegfilgrastim antibodies in serum were detected with an immunoassay using electroluminescence. The testing concept involved a multi-tiered approach. Initially, samples were subjected to a runspecific screening assay. If a sample result exceeded the cut point of the screening assay, then the sample was considered as ADA-reactive and was advanced to the next tier. Otherwise, the sample was considered negative, and no further tests were required on the sample.
All samples that were ADA positive in the screening assay were subsequently tested in a confirmatory assay. In the confirmatory assay, 
| Compliance with design and statistical analysis requirements
The study was designed to enroll equal subject numbers for each treatment sequence, and subjects were randomized in a 1:1 ratio.
Inclusion and exclusion criteria were predefined in the protocol. As there was a visible difference between the syringes for the test and reference products, drug administrations were performed by an unblinded team of medics and medically trained staff members, who
were not involved in any further study activities, and in a way that the subjects remained blinded. Subjects, investigator staff, persons performing the assessments or being responsible for determining dosing regimen and staff of the sponsor or data analysts, remained blinded from the time of randomization until database lock.
| RE SULTS
| Demographics and baseline characteristics
A total of 172 subjects were randomized and enrolled in the study (86 subjects for each treatment sequence). One subject was randomized but All subjects in this study were male and white. Thus, subject distribution by sex and race is not shown. Numbers are based on the primary analysis set (ie the model-based PK set; numbers are identical for the model-based PD set). Abbreviations: BMI = body mass index, Max = maximum, Min = minimum, N = number of subjects.
not treated, due to tachycardia in the predose ECG. Of the 171 subjects who received study medication, 8 subjects discontinued the study prematurely (5 for "personal reasons," 2 were lost to follow-up, 1 due to a protocol violation). A total of 163 subjects completed both study periods.
All subjects who received a dose of study medication were included in the safety set, whereas subjects who received a dose of study medication and who had adequate and reliable PK data from at least one study period were included in the PK set. Subjects who had evaluable PD data from at least one study period were included in the PD set. The model-based PK/ PD sets, used for the primary PK and PD analyses, respectively, included only subjects with data from both study periods, and without any protocol deviations which would render the data incomparable between treatments. Analysis sets are shown in Table 1 .
Demographics and baseline characteristics are shown in Table 2 for the primary analysis set (model-based PK and model-based PD set).
| Pharmacokinetics
Results are presented for the primary analysis set, the model-based PK set. This set includes all subjects with reliable data for both study periods, and without any important protocol deviation. Of the 171 subjects who received study medication, 10 were excluded from the model-based PK set, because they either discontinued prematurely and had reliable data for one study period only, or could not provide full PK profiles, for example, due to missing visits. Mean serum concentrations of pegfilgrastim after administration of Pelmeg and Neulasta were very similar, with maximum serum concentrations at around 24 hours postdose ( Figure 2 ).
The results for the statistical analysis of the primary PK parameters are shown in Table 3 . There was no relevant difference in the exposure of pegfilgrastim after administration of Pelmeg and Neulasta, as the 94.32% CIs for the ratio of the test and reference products were fully contained within the equivalence margin of 80.0%-125.0%. The primary PK endpoint of this study was met and PK comparability between test and reference was shown.
In addition to the prespecified analysis of AUC 0-last , also AUC 0-inf was analyzed, using the same model as described for the primary analysis. For this analysis, data from 143 subjects were available after Neulasta treatment and from 143 subjects after Pelmeg treatment (model-based PK set); there were 127 subjects with AUC 0-inf data from both periods. Abbreviations: ANC, absolute neutrophil count; AUC 0-last , area under the concentration time curve from time zero to last measurable concentration; AUEC 0-last , area under the effect time curve from time zero to last measurable concentration; CI, confidence interval; C max , maximum concentration; CV, coefficient of variation; N = number of subjects; PD = pharmacodynamics; PK, pharmacokinetic. a Intraindividual CV (%) estimated from the residual mean squares.
| Pharmacodynamics
Results are presented for the primary analysis set, which is the model-based PD set. This set includes all subjects with reliable data for both study periods, and without any relevant protocol deviation.
Of the 171 subjects who received study medication, 10 were excluded from the model-based PD set, because they either discontinued prematurely and had reliable data for one study period only, or could not provide full PD profiles, for example, due to missing visits.
Mean ANC values after administration of Pelmeg and Neulasta are shown in Figure 3 . ANC profiles were very similar after administration of Pelmeg and Neulasta. Starting from similar predose levels (around 3 G/L), comparable increases in mean ANC were observed. Peak levels were reached at around 3.5 days postdose and decreased thereafter.
The predose level was reached again on Day 18. Results for the statistical analysis of the primary PD parameter are shown in Table 3 .
The geometric mean ratio of AUEC 0-last was about 100% and the corresponding 95% CI was very close to 100%, indicating no difference with regard to ANC after administration of Pelmeg and Neulasta.
The primary PD endpoint of this study was met and PD comparability between test and reference was shown. Similar results after administration of Pelmeg and Neulasta were also observed for the secondary PD endpoints, geometric mean AUEC 0-last and E max of ANC, and CD34 + profiles.
| Safety
All 171 subjects dosed were included in the safety analysis. The percentage of subjects with any AE was comparable for Pelmeg and Neulasta (86.0% vs 81.3%, Table 4 ). In both groups, the majority of AEs were assessed as drug related by the investigator. In the majority of subjects, AEs were of mild or moderate severity. There were no deaths. One subject (treated with Pelmeg) reported the serious adverse event multiple injuries due to a car accident, assessed as unrelated to the study drug. Table 4 .
Injection site reactions were reported for six subjects after administration of Pelmeg (injection site erythema, injection site hematoma, and injection site warmth), and for one subject after administration of Neulasta (injection site erythema). Injection site reactions were assessed as mild in all subjects. No clinically meaningful differences between treatments were observed for any safety assessments, including laboratory, ECG, or vital signs (data not shown).
| Immunogenicity
A special focus of the safety evaluation was immunogenicity, which was evaluated as a secondary endpoint. A summary of ADA results is shown in Table 5 . Overall, 34 of 171 (19.9%) subjects in the safety set had confirmed ADA positive reactivity with PEG. Importantly, no anti filgrastim-reactive positive samples were detected in any subject. 
| D ISCUSS I ON
In line with the guidelines for biosimilar development, the focus of this clinical study was to confirm the biosimilarity of Pelmeg Rev 1). 13 Also, with regard to assessing the potential immunogenicity of pegfilgrastim, healthy subjects are considered more sensitive than cancer patients, as the latter have a compromised immune system.
In both healthy and patient populations, the mechanism of action of pegfilgrastim is the same, whereby pegfilgrastim elicits its effects on hematopoietic cells by binding to specific cell surface receptors stimulating proliferation and differentiation of committed progenitor cells of the granulocyte-neutrophil lineage into functionally mature neutrophils. Because the bone marrow in a healthy subject population is functionally unimpaired (in comparison with patients undergoing myelosuppressive chemotherapy), the bone marrow of this subject population is expected to be more responsive to stimulation with G-CSF. 14 The primary PD parameter ANC is an accepted surrogate marker and can be related to patient outcome to the extent that demonstration of a similar effect on the PD marker will ensure a similar effect on the clinical outcome (Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance:
nonclinical and clinical issues, EMEA/CHMP/BMWP/42832/2005
Rev 1).
The 6 mg dose of pegfilgrastim used in this study (ie the approved product dosage) is in the ascending part of the dose-response profile for AUC and C max , 15, 6 and is therefore considered to be sufficiently No. subjects (%) positive in nAb assay 0 (0%)
Abbreviations: ADA = anti-drug antibody, nAb = neutralizing antibody, N = number of subjects.
sensitive for assessment of PK. In order to account for the expected high variability of the relevant PK parameters, 6 the study method- 17 The variability of PK parameters was high, as previously suggested by a study in the literature. 6 The safety profile of Pelmeg was characterized by
AEs that are known adverse drug reactions of Neulasta, mainly musculoskeletal disorders and headache. Thereby, the frequencies and with G-CSF. 18 The results of that study showed that peripheral blood stem cell donors were not at increased risk for developing an autoimmune disease when compared to bone marrow donors. In addition, the US FDA has stated that they are unaware of reports of neutralizing antibodies to G-CSF products, concluding that the literature indicates that G-CSF products are low risk for causing ADA-related severe adverse effects (FDA, Transcript of FDA Adcom for Zarxio.
19
The safety data set for Pelmeg was reviewed in detail for AEs that could potentially be immune mediated, with a particular emphasis on hypersensitivity reactions. There were no AEs classified as hypersensitivity or drug hypersensitivity in subjects treated with either Pelmeg or Neulasta, and local tolerability was good. The results from this pivotal PK/PD study supported the initiation of a second clinical study with Pelmeg (Study B12019-102, EudraCT
No.: 2015-005022-19), which aimed to further investigate the immunogenicity and PD comparability after administration of Pelmeg and Neulasta to healthy subjects. The results from this study are reported separately.
| CON CLUS ION
This comparative PK/PD study in healthy subjects has demonstrated biosimilarity between Pelmeg and Neulasta for PK and PD at the clinical dose of 6 mg. No clinically meaningful differences in the safety or immunogenicity profiles were observed.
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